TORONTO / Jun 13, 2024 / Business Wire / NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 12, 2024. All figures are in Canadian dollars, unless otherwise noted.
The results of the director elections were as follows:
Name | Votes in | % Votes in | Votes | % Votes |
Jolyon Burton | 16,926,658 | 99.28% | 122,000 | 0.72% |
Daniel Chicoine | 16,926,658 | 99.28% | 122,000 | 0.72% |
Sasha Cucuz | 16,921,658 | 99.26% | 127,000 | 0.74% |
Dan Legault | 16,926,658 | 99.28% | 122,000 | 0.72% |
Joseph Walewicz | 16,926,658 | 99.28% | 122,000 | 0.72% |
The shareholders of the Company also voted: (i) to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Company for the ensuing year, and (ii) to approve the Company’s amended and restated stock option plan in the form attached as Schedule “A” to the management information circular dated April 23, 2024 prepared in connection with the Meeting.
About NeuPath
NeuPath operates a network of healthcare clinics and related businesses focused on improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. We operate a network of medical clinics in Ontario and Alberta that provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal/back injuries, sports related injuries and concussions. In addition, NeuPath provides workplace health services and independent medical assessments to employers and disability insurers through a national network of healthcare providers, as well as contract research services to pharmaceutical and biotechnology companies. NeuPath is focused on enabling each individual to live their best life. For additional information, please visit www.neupath.com.
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
| Last Trade: | C$0.19 |
| Daily Volume: | 25,500 |
| Market Cap: | C$10.720M |
November 14, 2024 August 15, 2024 April 10, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
